Nimotop is approved to prevent cerebral vasospasm in adults who have suffered an aneurysmal subarachnoid haemorrhage. The standard regimen is 30 mg taken every 4 hours for up to 21 days.
Nimodipine is not approved for routine hypertension treatment. Although it has vasodilatory properties, evidence for blood-pressure control is limited, and off-label use should only occur under specialist supervision.
Nimodipine shows a higher affinity for cerebral blood vessels, making it especially effective at preventing vasospasm after brain bleed. In contrast, amlodipine is designed for systemic blood-pressure reduction and is widely used for hypertension.
Avoid large quantities of grapefruit juice, as it can inhibit CYP3A4 metabolism and increase drug levels, potentially causing excessive lowering of blood pressure.
Severe dizziness may signal hypotension. Sit or lie down immediately, avoid driving, and contact your healthcare provider promptly for evaluation and possible dose adjustment.
Pregnancy is classified as category C; animal studies suggest risk, and human data are insufficient. Nimodipine is excreted in breast milk, so breastfeeding is generally not recommended while on the medication.
The tablet should be swallowed whole. Crushing or splitting may affect the drug’s release profile and absorption, potentially altering its effectiveness.
Check the expiry date printed on the packaging. Generally, tablets remain stable for up to two years when stored at room temperature, protected from moisture and light.
Signs include profound hypotension, dizziness, and fainting. Treatment is supportive, often involving intravenous fluids and medications to raise blood pressure. Seek emergency medical care immediately if overdose is suspected.
Nimotop is a brand-name medication that contains the active ingredient nimodipine. Nimodipine belongs to the calcium-channel blocker class, specifically the dihydropyridine subgroup, and is formulated as a 30 mg oral pill. In Hong Kong, Nimotop is a prescription-only product regulated by the Department of Health. The medication is primarily used to reduce the risk of cerebral vasospasm following a subarachnoid haemorrhage, but its pharmacologic properties also affect systemic blood pressure and heart function.
Nimodipine selectively blocks L-type calcium channels in the smooth muscle of blood vessels. By inhibiting calcium entry, the drug causes vascular smooth-muscle relaxation, leading to dilation of arterial walls. This effect is especially pronounced in the cerebral circulation, where nimodipine improves blood flow and helps prevent the narrowing (vasospasm) that can occur after a subarachnoid bleed.
The onset of action occurs within 30 minutes after oral administration, with peak plasma concentrations typically reached in 1-2 hours. The drug’s half-life is about 8-9 hours, supporting multiple-daily dosing to maintain steady vascular effects.
Nimotop is approved in Hong Kong for the following indication:
While nimodipine is a calcium-channel blocker, it is not approved for routine treatment of hypertension or other cardiovascular conditions in Hong Kong. Its use outside the approved indication is considered off-label and should only occur under specialist supervision.
Off-label use of Nimotop requires medical supervision and individualized risk assessment.
Ideal candidates are adults who have recently experienced a subarachnoid haemorrhage and require prevention of cerebral vasospasm.
Absolute contraindications
Relative contraindications
Special populations such as the elderly may require closer monitoring of blood pressure and heart rate due to altered drug clearance.
These events are usually transient and may lessen with continued therapy.
If any of these occur, seek immediate medical attention.
Patients should inform their healthcare provider of all medicines, supplements, and herbal products before starting Nimotop.
Dosing must be individualized by a qualified healthcare professional based on the patient’s clinical status.
This article provides educational information about Nimotop and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
